Magenta Therapeutics Inc Forecast, price target & analysts
Magenta Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Magenta Therapeutics Inc Classifications & Recommendation:
Magenta Therapeutics Inc Price Target
| Target Price | $52.60 |
| Price | $16.12 |
| Potential |
226.30%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Magenta Therapeutics Inc 2026 .
The average Magenta Therapeutics Inc target price is $52.60.
This is
226.30%
register free of charge
$84.00
421.09%
register free of charge
$36.00
123.33%
register free of charge
|
|
| A rating was issued by 12 analysts: 12 Analysts recommend Magenta Therapeutics Inc to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Magenta Therapeutics Inc stock has an average upside potential 2026 of
226.30%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 6.24 | 3.52 |
| 120.49% | 43.67% | |
| Net Margin | -1,271.73% | -3,197.58% |
| 86.31% | 151.44% |
10 Analysts have issued a sales forecast Magenta Therapeutics Inc 2025 . The average Magenta Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
6 Magenta Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Magenta Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.55 | -3.61 |
| 69.82% | 41.57% | |
| P/E | negative | |
| EV/Sales | 69.45 |
6 Analysts have issued a Magenta Therapeutics Inc forecast for earnings per share. The average Magenta Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Magenta Therapeutics Inc...
Current Magenta Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Dec 20 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
| Raymond James |
Locked
➜
Locked
|
Locked | Nov 08 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Dec 20 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 11 2024 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Nov 11 2024 |
|
Locked
Raymond James:
Locked
➜
Locked
|
Nov 08 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
